Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer
2015 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Erlotinib and bevacizumab versus cisplatin, gemcitabine and bevacizumab in unselected nonsquamous nonsmall cell lung cancer
Thomas, M.; Fischer, J.; Andreas, S.; Kortsik, C.; Grah, C.; Serke, M. & von Eiff, M. et al. (2015)
European Respiratory Journal, 46(1) pp. 219-229. DOI: https://doi.org/10.1183/09031936.00229014
Documents & Media
Details
- Authors
- Thomas, Michael; Fischer, Juergen; Andreas, Stefan; Kortsik, Cornelius; Grah, Christian; Serke, Monika; von Eiff, Michael; Witt, Christian; Kollmeier, Jens; Mueller, Ernst; Schenk, Michael; Schroeder, Michael; Villalobos, Matthias; Reinmuth, Niels; Penzel, Roland; Schnabel, Philipp A.; Acker, Thomas; Reuss, Alexander; Wolf, Martin
- Abstract
- Erlotinib with bevacizumab showed promising activity in recurrent nonsquamous (NS) nonsmall cell lung cancer (NSCLC). The INNOVATIONS study was designed to assess in first-line treatment of unselected cisplatin-eligible patients this combination compared to cisplatin, gemcitabine and bevacizumab. Stage IIIB/IV patients with NS-NSCLC were randomised on erlotinib (150 mg daily) and bevacizumab (15 mg . kg(-1) on day 1, every 3 weeks) (EB) until progression, or cisplatin (80 mg . m(-2) on day 1, every 3 weeks) and gemcitabine (1250 mg . m(-2) on days 1 and 8, every 3 weeks) up to six cycles and bevacizumab (15 mg . kg(-1) on day 1, every 3 weeks) (PGB) until progression. 224 patients were randomised (EB n=111, PGB n=113). The response rate (12% versus 36%; p<0.0001), progression-free survival (median 3.5 versus 6.9 months; hazard ratio (HR) 1.85, 95% CI 1.39-2.45; p<0.0001) and overall survival (median 12.6 versus 17.8 months; HR 1.41, 95% CI 1.01-1.97; p=0.04) clearly favoured PGB. In patients with epidermal growth factor receptor mutations (n=32), response rate, progression-free survival and overall survival were not superior with EB. Platinum-based combination chemotherapy remains the standard of care in first-line treatment of unselected NS-NSCLC. Molecular targeted approaches strongly mandate appropriate testing and patient selection.
- Issue Date
- 2015
- Status
- published
- Publisher
- European Respiratory Soc Journals Ltd
- Journal
- European Respiratory Journal
- ISSN
- 1399-3003; 0903-1936
- Sponsor
- Roche, Germany